Osteoporosis associated with the treatment of paraphilias: A clinical review of seven case reports

Journal of Forensic Sciences

Volumn 48, Issue 4, 2003, Pages 849-855

  Grasswick, Linda J ^a   Bradford, John M W ^b  

^a Youth Forensic Psychiatric Services   (Canada)

^b ROYAL OTTAWA HEALTH CARE GROUP   (Canada)

Author keywords

Bilateral orchidectomy; Cyproterone acetate; Forensic psychiatry; Forensic science; Leuprolide; Osteoporosis

Indexed keywords

CARBAMAZEPINE; CELECOXIB; CYPROTERONE ACETATE; ETIDRONIC ACID; GONADORELIN AGONIST; LEUPRORELIN; MEDROXYPROGESTERONE ACETATE; RANITIDINE;

ADULT; BONE DENSITY; CASTRATION; CLINICAL ARTICLE; CONFERENCE PAPER; GYNECOMASTIA; HOT FLUSH; HUMAN; HYPERCALCEMIA; IRON DEFICIENCY ANEMIA; LIBIDO DISORDER; LIVER DYSFUNCTION; MALE; METABOLIC DISORDER; OSTEOPENIA; OSTEOPOROSIS; PATIENT MONITORING; PRIORITY JOURNAL; SEXUAL DEVIATION; THROMBOEMBOLISM; WEIGHT GAIN;

EID: 0038387655     PISSN: 00221198     EISSN: None     Source Type: Journal    
DOI: 10.1520/jfs2002089     Document Type: Conference Paper

References (62)

1. Bradford JMW. The neurobiology, neuropharmacology, and pharmacological treatment of the paraphilias and compulsive sexual behaviour. Can J Psychiatry 2001;46:26-34.
2. Abel GG, Osborn C, Anthony D, Gardos P. Current treatments of paraphilias. Annual Review of Sex Res 1992;3:255-90.
3. Bradford JMW, Pawlak A. Double-blind placebo crossover study of cyproterone acetate in the treatment of the paraphilias. Arch Sex Behavior 1993;22:383-402.
4. Cooper AJ, Sandhu S, Losztyn S, Cernovsky Z. A double-blind placebo controlled trial of medroxyprogesterone acetate and cyproterone acetate with seven pedophiles. Can J Psychiatry 1992;37:687-93.
5. Rosler A, Witztum E. Treatment of men with paraphilia with a long-acting analogue of gonadotropin-releasing hormone. N Engl J Med 1998;338:416-22.
6. Thibaut F, Cordier B, Kuhn J-M. Effect of a long-lasting gonadotrophin hormone-releasing hormone agonist in six cases of severe male paraphilia. Acta Psychiatr Scand 1993;87:445-50.
7. Sturup GK. Castration: the total treatment. In: Resnick HLP, Wolfgang ME, editors. Sexual behaviours: social, clinical and legal aspects. Massachusetts: Little Brown, 1972;361-82.
8. Heim N, Hursch CJ. Castration for sexual offenders: Treatment or punishment? A review and critique of recent European literature. Arch Sex Behav 1977;8:281-304.
9. Melton LJ III, Chrischilles EA, Lane AW, Riggs BL. How many women have osteoporosis? J Bone Miner Res 1992;9:1005-10.
10. Kanis JA, McCloskey EV. Epidemiology of vertebral osteoporosis. Bone 1992;13:S1-S10.
11. Martin AD, Silverthorn KG, Houston CS. The incidence of fracture of the proximal femur in two million Canadians from 1972 to 1984. Clin Orthop 1991;266:111-18.
12. Scientific Advisory Board, Osteoporosis Society of Canada. Clinical practice guidelines for the diagnosis and management of osteoporosis. CMAJ 1996;155:1113-33.
13. Wade JP. Rheumatology: 15. Osteoporosis. CMAJ 2001;165(1)45-50.
14. http://www.nof.org/advocacy/prevalence.
15. Looker AC, Orwoll ES, Johnston CC Jr, Lindsay RL, Wahner HW, Dunn WL et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 1997 Nov;12(11):1761-8.
16. Eastell R, Boyle IT, Compston J, Cooper C, Fogelman I, Francis RM, et al. Management of male osteoporosis: report of the UK consensus group. Q J Med 1998 Feb;91(2):71-92.
17. Bilezikian JP. Osteoporosis in men. J Clin Endocr Metab 1999;84:3431-4.
18. Ross RW, Small EJ. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol 2002 May; 167:1952-6.
19. Schot LP, Schuurs AH. Sex steroids and osteoporosis: effects of deficiencies and substitute treatments. J Steroid Biochem Mol Biol 1990;37:167-88.
20. Tannirandorn P, Epstein S. Drug-induced bone loss. Osteoporos Int 2000;11(8):637-59.
21. Amin S, Zhang Y, Sawin CT, Evans SR, Hannan MT, Kiel DP et al. Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham study. Ann Intern Med 2000 Dec 19;133(12):951-63.
22. Colao A, Di Somma C, Loche S, Di Sarno A, Klain M, Pivonello R, et al. Prolactinomas in adolescents: persistent bone loss after 2 years of pro-lactin normalization. Clin End 2000;52(3):319-27.
23. Sanfilippo JS. Implications of not treating Hyperprolactinemia. J Rep Med 1999 Dec;44(12 Suppl):1111-5.
24. Adler RA, Evani R, Mansouri A, Krieg RJ Jr. Relative effects of pro-lactin excess and estrogen deficiency on bone in rats. Metabolism 1998;47(4):425-8.
25. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990;112:352-64.
26. Michel BA, Bloch DA, Wolfe R, Fries JF. Fractures in rheumatoid arthritis: an evaluation of associated risk factors. J Rheumatol 1993;20:1666-9.
27. Dykman TR, Gluck OS, Murphy WA, Hahn TJ, Hahn BH. Evaluation of factors associated with glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum 1985;28:361-8.
28. Rosler A, Witztum E. Treatment of men with paraphilia with a long-acting analogue of gonadtropin-releasing hormone. NEJM 1998;338:416-22.
29. Berlin FS, Meinecke CF. Treatment of sex offenders with antiandrogen medication: Conceptualization, review of treatment modalities, and preliminary findings. Am J Psychiatry 1981;138(5):601-7.
30. Daniell HW. Osteoporosis after orchidectomy for prostate cancer. J Urol 1997;157(2):439-44.
31. th ed. New York: McGraw-Hill Inc., 1991;1713-35.
32. Winslade W, Stone TH, Smith-Bell M, Webb DM. Castrating pedophiles convicted of sex offenses against children: new treatment or old punishment? SMU Law Review 1998;51(2):349-411.
33. Eriksson S, Eriksson A, Stege R, Carlstrom K. Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcified Tissue Int 1995 Aug;57(2):97-9.
34. Stepan JJ, Lachman M, Zverina J, Pacovsky V, Baylink DJ. Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocr Met 1989 Sept;69(3):532-7.
35. Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000 Jan 163(1):181-6.
36. Canadian Pharmaceutical Association. Compendium of pharmaceutical and specialties. Ottawa: Canadian Pharmaceutical Association, 2000.
37. Kuret JA, Murad F. Adenohypophyseal hormones and related substances. In: Gilman AG, Rall TW, Nies AS, Taylor P, editors. The pharmacological basis of therapeutics. New York: Pergamon Press, 1990;1334-60.
38. Geller J. Overview of enzyme inhibitors and anti-androgen in prostatic cancer. J Androl 1991;12:364-70.
39. Leder BZ, Smith MR, Fallon MA, Lee ML, Finkelstein JS. Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men. J Clin Endocr Metab 2001;86(2):511-6.
40. Dawood MY, Ramos J, Khan-Dawood FS. Depot leuprolide acetate versus danazol for treatment of pelvic endometriosis: changes in vertebral bone mass and serum estradiol and calcitonin. Fertil Steril 1995 Jun;63(6):1177-83.
41. Hatano T, Oishi Y, Furuta A, Iwamuro S, Tashiro K. Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int 2000 Sep;86(4):449-52.
42. Paoletti AM, Serra GG, Cagnacci A, Vacca AM, Guerriero S, Solla E et al. Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment. Fertil Steril 1996;65(4):707-10.
43. Wilson JD. Androgens. In: Gilman AG, Rall TW, Nies AS, Taylor P, editors. The Pharmacological Basis of Therapeutics. New York: Pergamon Press, 1990;1413-30.
44. de Voogt HJ, Smith PH, Pavone-Macaluso M, de Pauw M, Suciu S. Cardiovascular side effects of diethylstilbesterol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. J Urol 1986;135:303-7.
45. Reilly DR, Delva J, Hudson RW. Protocols for the use of cyproterone, medroxyprogesterone, and leuprolide in the treatment of paraphilia. Can J Psychiatry 2000;45:559-63.
46. Parys BT, Hamid S, Thomson RG. Severe hepatocellular dysfunction following cyproterone acetate therapy. Br J Urol 1991;67:312-3.
47. Strum SB, McDermed JE, Scholz MC, Johnson H, Tisman G. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 1997;79:933-41.
48. Castelo-Branco C, Martinez de Osaba MJ, Pons F, Vanrell JA. Effects of bone mass of two oral contraceptives containing ethinylestradiol and cyproterone acetate or desogestrel: results of a 2-year follow-up. Eur J Contraception & Rep Health Care 1998;3(2):79-84.
49. Komulainen J, Kroger H, Tuppurainen MT, Keikkinen AM, Alhava E, Honkanen R et al. Prevention of femoral and lumbar bone loss with hormone replacement therapy and vitamin D3 in early postmenopausal women: a population-based 5-year randomized trial. J Clin Endocrin Met 1999 Feb;84(2):546-62.
50. Marslew U, Overgaard K, Riis BJ, Christiansen C. Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding. Obstet Gynecol 1992;79(2):202-10.
51. De Cree C, Lewin R, Ostyn M. Suitability of cyproterone acetate in the treatment of osteoporosis associated with athletic amenorrhea. Int J Sports Med 1988;9(3):187-92.
52. Vasireddy S, Swinson DR. Male osteoporosis associated with longterm cyproterone treatment. J Rheum 2001 Jul;28(7):1702-3.
53. Hierl T, Boresok I, Ziegler R, Kasperk C. Osteo-anabolic estrogen therapy in a transsexual man. Dtsch Med Wochenschr 1999 Apr30; 124(17):519-22.
54. American Association of Clinical Endocrinologists. 2001 medical guidelines for clinical practice for the prevention and management of post-menopausal osteoporosis. Endocrine Practice 2001;7(4):293-312.
55. Bill C-30, An act to amend the criminal code and to amend the national defense act and the young offenders act in consequence thereof, S.C. c. 43.
56. Bradford JMW, Pawlak A. Sadistic homosexual pedophilia: treatment with cyproterone acetate: a single case study. Can J Psychiatry 1987;32:22-30
57. Kiratli BJ, Srinivas S, Perkash I, Terris MK. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 2001;57:127-32.
58. Kafka MP, Prentky R. Comparative study of non-paraphilic sexual addictions and paraphilias in men. J Clin Psychiatry 1991;53:345-50.
59. Kafka MP. Sertraline pharmacotherapy for paraphilias and paraphilia-related disorder: an open trial. Ann Clin Psych 1994;6:189-95.
60. Greenberg DM, Bradford JMW, Curry S, O'Rourke A. A comparison of treatment of paraphilias with three serotonin reuptake inhibitors: a retrospective study. Bull Am Acad Psych Law 1996;24:525-32.
61. Bradford JMW. The treatment of sexual deviation using a pharmacological approach. J of Sex Research 2000;37:248-57.
62. Winko v. British Columbia (Forensic Psychiatric Institute) [1999] 2 S.C.R. 625.